193 related articles for article (PubMed ID: 23708655)
41. A DNA-binding mutant of TAL1 cooperates with LMO2 to cause T cell leukemia in mice.
Draheim KM; Hermance N; Yang Y; Arous E; Calvo J; Kelliher MA
Oncogene; 2011 Mar; 30(10):1252-60. PubMed ID: 21057528
[TBL] [Abstract][Full Text] [Related]
42. LMO2 attenuates tumor growth by targeting the Wnt signaling pathway in breast and colorectal cancer.
Liu Y; Huang D; Wang Z; Wu C; Zhang Z; Wang D; Li Z; Zhu T; Yang S; Sun W
Sci Rep; 2016 Oct; 6():36050. PubMed ID: 27779255
[TBL] [Abstract][Full Text] [Related]
43. Diagnostic utility of LMO2 immunohistochemistry in distinguishing T-lymphoblastic leukemia/lymphoma from thymoma.
Bansal D; Pasricha S; Gupta G; Sharma A; Durga G; Kamboj M; Mehta A
Indian J Pathol Microbiol; 2024; 67(1):141-144. PubMed ID: 38358204
[TBL] [Abstract][Full Text] [Related]
44. Conformational flexibility of the oncogenic protein LMO2 primes the formation of the multi-protein transcription complex.
Sewell H; Tanaka T; El Omari K; Mancini EJ; Cruz A; Fernandez-Fuentes N; Chambers J; Rabbitts TH
Sci Rep; 2014 Jan; 4():3643. PubMed ID: 24407558
[TBL] [Abstract][Full Text] [Related]
45. Conditional Immortalization of Lymphoid Progenitors via Tetracycline-Regulated
Koniaeva E; Stahlhut M; Lange L; Sauer MG; Kustikova OS; Schambach A
Hum Gene Ther; 2020 Feb; 31(3-4):183-198. PubMed ID: 31760808
[TBL] [Abstract][Full Text] [Related]
46. Upstream distal regulatory elements contact the Lmo2 promoter in mouse erythroid cells.
Bhattacharya A; Chen CY; Ho S; Mitchell JA
PLoS One; 2012; 7(12):e52880. PubMed ID: 23285212
[TBL] [Abstract][Full Text] [Related]
47. The oncogenic LIM-only transcription factor Lmo2 regulates angiogenesis but not vasculogenesis in mice.
Yamada Y; Pannell R; Forster A; Rabbitts TH
Proc Natl Acad Sci U S A; 2000 Jan; 97(1):320-4. PubMed ID: 10618416
[TBL] [Abstract][Full Text] [Related]
48. A comprehensive analysis of LMO2 pathogenic regulatory profile during T-lineage development and leukemic transformation.
Wang W; Meng Y; Chen Y; Yu Y; Wang H; Yang S; Sun W
Oncogene; 2022 Aug; 41(34):4079-4090. PubMed ID: 35851847
[TBL] [Abstract][Full Text] [Related]
49. FOXP3 can modulate TAL1 transcriptional activity through interaction with LMO2.
Fleskens V; Mokry M; van der Leun AM; Huppelschoten S; Pals CE; Peeters J; Coenen S; Cardoso BA; Barata JT; van Loosdregt J; Coffer PJ
Oncogene; 2016 Aug; 35(31):4141-8. PubMed ID: 26686090
[TBL] [Abstract][Full Text] [Related]
50. BRACHYURY directs histone acetylation to target loci during mesoderm development.
Beisaw A; Tsaytler P; Koch F; Schmitz SU; Melissari MT; Senft AD; Wittler L; Pennimpede T; Macura K; Herrmann BG; Grote P
EMBO Rep; 2018 Jan; 19(1):118-134. PubMed ID: 29141987
[TBL] [Abstract][Full Text] [Related]
51. Enforced expression of E47 has differential effects on Lmo2-induced T-cell leukemias.
Goodings C; Tripathi R; Cleveland SM; Elliott N; Guo Y; Shyr Y; Davé UP
Leuk Res; 2015 Jan; 39(1):100-9. PubMed ID: 25499232
[TBL] [Abstract][Full Text] [Related]
52. LMO2 promotes tumor cell invasion and metastasis in basal-type breast cancer by altering actin cytoskeleton remodeling.
Liu Y; Wang Z; Huang D; Wu C; Li H; Zhang X; Meng B; Li Z; Zhu T; Yang S; Sun W
Oncotarget; 2017 Feb; 8(6):9513-9524. PubMed ID: 27880729
[TBL] [Abstract][Full Text] [Related]
53. LMO2 Is a Specific Marker of T-Lymphoblastic Leukemia/Lymphoma.
Jevremovic D; Roden AC; Ketterling RP; Kurtin PJ; McPhail ED
Am J Clin Pathol; 2016 Feb; 145(2):180-90. PubMed ID: 26796495
[TBL] [Abstract][Full Text] [Related]
54. Notch1 inhibition targets the leukemia-initiating cells in a Tal1/Lmo2 mouse model of T-ALL.
Tatarek J; Cullion K; Ashworth T; Gerstein R; Aster JC; Kelliher MA
Blood; 2011 Aug; 118(6):1579-90. PubMed ID: 21670468
[TBL] [Abstract][Full Text] [Related]
55. Are Leukaemic Stem Cells Restricted to a Single Cell Lineage?
Brown G; Sánchez L; Sánchez-García I
Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31861691
[TBL] [Abstract][Full Text] [Related]
56. Overexpression of Lmo2 initiates T-lymphoblastic leukemia via impaired thymocyte competition.
Abdulla HD; Alserihi R; Flensburg C; Abeysekera W; Luo MX; Gray DHD; Liu X; Smyth GK; Alexander WS; Majewski IJ; McCormack MP
J Exp Med; 2023 Jun; 220(6):. PubMed ID: 36920307
[TBL] [Abstract][Full Text] [Related]
57. LIM domain only 2 protein expression, LMO2 germline genetic variation, and overall survival in diffuse large B-cell lymphoma in the pre-rituximab era.
Cerhan JR; Natkunam Y; Morton LM; Maurer MJ; Asmann Y; Habermann TM; Vasef MA; Cozen W; Lynch CF; Allmer C; Slager SL; Lossos IS; Chanock SJ; Rothman N; Hartge P; Dogan A; Wang SS
Leuk Lymphoma; 2012 Jun; 53(6):1105-12. PubMed ID: 22066713
[TBL] [Abstract][Full Text] [Related]
58. Identification of DeltaEF1 as a novel target that is negatively regulated by LMO2 in T-cell leukemia.
Sun W; Yang S; Shen W; Li H; Gao Y; Zhu TH
Eur J Haematol; 2010 Dec; 85(6):508-19. PubMed ID: 20731704
[TBL] [Abstract][Full Text] [Related]
59. LMO2 Enhances Lamellipodia/Filopodia Formation in Basal-Type Breast Cancer Cells by Mediating ARP3-Profilin1 Interaction.
Liu Y; Wu C; Zhu T; Sun W
Med Sci Monit; 2017 Feb; 23():695-703. PubMed ID: 28170369
[TBL] [Abstract][Full Text] [Related]
60. High expression of LMO2 in Hodgkin, Burkitt and germinal center diffuse large B cell lymphomas.
Shams TM
J Egypt Natl Canc Inst; 2011 Dec; 23(4):147-53. PubMed ID: 22776842
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
